The Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation

Abstract

Objective. The objective of this study is to examine the effect of country-specific EQ-5D preference weights on the cost-effectiveness (CE) of initial pramipexole versus levodopa strategy in patients with Parkinson disease (PD). Methods. A total of 301 subjects with PD were randomized to initial pramipexole or levodopa and followed every 3 months over a 4-year period. Subjects' health-related quality of life (HRQOL) was measured using EQ-5D, and their health preferences were calculated using both the UK and US sets of weights. The effectiveness of pramipexole was defined as the additional quality-adjusted life-years (QALY) gained compared to levodopa and was estimated as the area between the treatment-specific HRQOL profiles adjusted for baseline difference. Results. Using the original UK weights, the incremental effectiveness was 0.155 QALYs, which resulted in the incremental CE ratio (ICER) of $42,989/QALY and a probability that pramipexole was cost-effective relative to levodopa of 0.57, 0.77, and 0.82 when a QALY was valued at $50,000, $100,000, and $150,000, respectively. Using the US-specific weights resulted in lower incremental effectiveness (0.062 QALYs), higher ICER ($108,498/QALY), and a lower probability that pramipexole was cost-effective compared to levodopa at any valuation of QALY (0.23 for $50,000, 0.48 for $100,000, and 0.58 for $150,000). Conclusions. Country-specific preference weights in clinical-economic trials might have important effects on estimates of incremental cost-effectiveness. Using US preference weights rather than UK preference weights reduced the probability that pramipexole was cost-effective compared to levodopa.

Keywords

Key words: Parkinson disease EQ-5D quality of life cost-effectiveness pramipexole levodopa. (Med Decis Making 2007;27:327—334)

Get full access to this article

View all access options for this article.

References

Furlong WJ , Feeny DH , Torrance GW , Barr RD The Health Utility Index (HUI) system for assessing health-related quality of life in clinical studies . Ann Med. 2001 ;33: 375—84 .

Andersen EM , Rothenberg BM , Kaplan RM Performance of self-administered mailed version of the quality of well-being (QWNS-SA) questionnaire among older adults. Med Care. 1998; 36: 1349—60 .

EuroQol Group. EuroQol—a new facility for the measurement of health related quality of life . Health Policy. 1990;12: 199—208 .

Drummond MF , Sculpher MJ , Torrance GW , O'Brien BJ , Stoddart GL Methods for Economic Evaluation of Health Care Programmes. 3rd ed. Oxford (UK): Oxford University Press ; 2005.

Ramsey S. , Willke R. , Briggs A. , et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report . Value Health. 2005;8(5): 521—33 .

Dolan P. Modelling valuations for EuroQol health states . Med Care. 1997;35: 1095—108 .

LaGales C. , Burton C. , Costet N. , Rosman S. , Slama C. Development of a preference-weighted health status classification system in France: the Health Utilities Index . Health Care Manag Sci. 2002;5: 41—51 .

Johnson JA , Luo N. , Shaw JW , Kind P. , Coons SJ

Valuations of EQ-5D health states: are the United States and United Kingdom different?

Med Care. 2005;43(221): 228 .

Hanmer J. , Lawrence WF , Anderson JP , Kaplan RM , Fryback DG Report of nationally representative values for the non-institutionalized U.S. adult population for seven health related quality of life scores . Med Decis Making. 2006;26: 391—400 .

10.

Shaw JW , Johnson JA , Coons SJ US valuation of the EQ-5D health states: development and testing of the D1 valuation model . Med Care. 2005;43: 302—20 .

11.

Noyes K. , Dick AW , Holloway RG, Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial . Med Decis Making. 2004;24: 472—85 .

12.

Noyes K. , Dick AW , Holloway RG, Parkinson Study Group. Dynamic changes in cost-effectiveness: comparing pramipexole and levodopa in early Parkinson's disease . Pharmacoeconomics. 2005;23(12): 1257—70 .

13.

Noyes K. , Dick AW , Holloway RG

Pramipexole v levodopa in patients with early Parkinson's disease: effect on health-related quality of life. Value

Health. 2005;9(1): 28—38 .

14.

Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial . JAMA. 2000;284: 1931—8 .

15.

Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial . Arch Neurol. 2004;61: 1044—53 .

16.

Noyes K. , Dick AW , Holloway RG, Parkinson Study Group. Quality of life assessment of early Parkinson's disease patients . Med Decis Making. 2003;23(6): 248 .

17.

Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study . Clin Neuropharmacol. 2000;23(1): 34—44 .

18.

Ramsey SD , McIntosh M. , Sullivan SD Design issues for conducting cost-effectiveness analyses alongside clinical trials . Ann Rev Public Health. 2001;22: 129—41 .

19.

Fahn S. , Elton RL , members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S , Marsden CD , Calne DB , Goldstein M , eds. Recent Developments in Parkinson's Disease. Vol2. F lorham Park (NJ): Macmillan Health Care Information ; 1987. p 153—64.

20.

Rabin R. , de Charro F. EQ-5D: a measure of health status from the EuroQol Group . Ann Med. 2001;33: 337—43 .

21.

Gold MR , Siegel JE , Russell LB , Weinstein MC Cost-Effectiveness in Health and Medicine. New York: Oxford University Press ; 1996.

22.

Siderowf A. , Ravina B. , Glick HA Preference-based quality-of-life in patients with Parkinson's disease . Neurology. 2002;59(1): 103—8 .

23.

Brazier JE , Walters SJ , Nicholl JP , et al. Using the SF-36 and Euroqol on an elderly population . Qual Life Res. 1996;5(2): 195—204 .

24.

Torrance GW , Tugwell P. , Amorosi S. , et al. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate . Rheumatology. 2004;43: 712—8 .

25.

US Department of Labor. Consumer Price Index. Available from: URL:http://www.blsgov/cpi 2005

26.

Hoch JS , Briggs AH , Willan AR Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis . Health Econ. 2002;11(5): 415—30 .

27.

Stinnett AA , Mulahy J. Net health benefit: a new framework for the analysis of uncertainty in cost-effectiveness analysis . Med Decis Making. 1998;18(suppl): S68—S80 .

28.

Fenwick E. , O'Brien BJ , Briggs A. Cost-acceptability curves— facts, fallacies and frequently asked questions . Health Econ. 2004;13(5): 405—15 .

29.

VanHout BA , Al MJ , Gordon GS , et al. Cost, effects and C/E ratios alongside a clinical trial . Health Econ. 1994;3: 309—19 .

30.

Ubel PA , Hirth RA , Chernew ME , et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14): 1637—41 .

31.

Perkins HS , Geppert CM , Gonzales A. , Cortez JD , Hazuda HP Cross-cultural similarities and differences in attitudes about advance care planning . J Gen Intern Med. 2002;17(1): 48—57 .

32.

Braun KL , Nichols R. Death and dying in four Asian American cultures: a descriptive study . Death Stud. 1997;21(4): 327—59 .

33.

Braun KL , Nichols R. Cultural issues in death and dying . Hawaii Med J. 1996;55(12): 260—4 .

34.

Hallenbeck J. , Goldstein MK , Mebane EW Cultural considerations of death and dying in the United States . Clin Geriatr Med. 1996 ;12(2): 393—406 .

35.

Langfitt JT , Vickrey B. , McDermott MP , et al. Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy . Qual Life Res. 2006;15(5): 899—914 .